Global Cancer Vaccine Market & Clinical Trial Insight

September 2015 | 750 pages | ID: G073617F1BDEN
Kuick Research

Abstracts

Please note: extra shipping charges are applied when purchasing Hard Copy License depending on the location.

The concept of vaccines dates back to1881, when Edward Jenner developed the first vaccine to treat small pox. Since then many technological advancements have been made, in modern times, vaccines have been developed as a new therapeutic for prevention and eradication of cancer. Currently, ranges of therapeutics are available in market to effectually combat cancer, but they suffer from several glitches like low effectiveness and high unspecificity. Researchers came up with the idea of cancer vaccines to alleviate patients suffering from cancer.

Conventionally, vaccines were used for the prevention of contagious diseases, they work by boosting the immune response against the pathogens. Analogously, cancer vaccines work by activating the immune system to attack on cancer cells. Researchers developed cancer vaccines to alleviate patients suffering from cancer. With the technological advances, cancer vaccines have been developed as a new therapeutic for cancer prevention and eradication. Currently, ranges of therapeutics are available in market to effectually combat cancer, but they suffer from several glitches like low effectiveness and high unspecificity.

The cancer vaccines have revolutionized the present views and methodologies of cancer treatment. As a result of which plenty of biotech companies are exploring the field of cancer vaccines. This has caused the development of numerous cancer vaccines for numerous types of cancer. Pharmaceutical companies are using these vaccines for clinical trials; few of them are already available to the patients across the world. The US and EU were the first markets to approve the cancer vaccines for therapeutic usage. As compared to rest of the world, commercialization and development in these regions have already made a significant progress.

The attractiveness for cancer vaccines has increased in past few years due to their characteristic properties like less side effects, low toxicity and high specificity. Besides, innovations related to novel delivery methods have also made them a lucrative option. Unlike traditional methods, they can be used for targeting the sub-group of cancers without effecting normal cells. Another factor in their favor is their high efficacy levels as compared to the presently available cancer therapeutics.

The market size of cancer vaccines category is many fold smaller than other cancer therapeutics categories. Due to nascent stages of industry-life cycle and late introduction in market has decreased their overall share. To tap this cancer market category, many global companies are actively investing in cancer vaccine development. The market penetration is expected to increase with the competition among various pharmaceutical companies to get a larger portion of this market category.

The cancer vaccines have to go through a long journey before enjoying the status of blockbuster drug. Presently, they have achieved a lot of success in both therapeutic and preventive field. However, inclination of market and researchers seems to be more towards the preventive category of cancer vaccines. For therapeutic side, it should be noted that novel methods for cancer eradication has been made. The future of cancer vaccines looks optimistic and plenty of cancer vaccines will hit the shelf in coming years.

“Global Cancer Vaccine Market & Clinical Trial Insight” Report Highlights:

• Global Cancer Market Overview
• Emergence of Personalized Cancer Vaccines
• Platforms for Cancer Vaccines Delivery
• Mechanism of Cancer Vaccines
• Global Cancer Vaccines Clinical Pipeline by Phase, Indication, Company & Country
• Global Cancer Vaccine Clinical Pipeline: 298 Vaccines
• Marketed Cancer Vaccines: 15 Vaccines
• Regulatory Framework for Cancer Vaccines Development & Marketing

Contents

1. INTRODUCTION TO CANCER VAACINES

2. MECHANISM OF CANCER VACCINES

2.1 Idiotype Cancer Vaccine Mechanism
2.2 Cellular Cancer Vaccines Mechanism
2.3 Ganglioside Antigens based Cancer Vaccines Mechanism
2.4 Peptide Cancer Vaccine Mechanism
2.5 Tumor Host Interaction Cancer Vaccine Mechanism

3. ADJUVANTS THERAPY FOR CANCER VACCINES

4. GLOBAL CANCER VACCINES MARKET OVERVIEW

4.1 Current Market Scenario
4.2 Global Cancer Vaccine Drug Pipeline by Indication

5. EMERGENCE OF PERSONALIZED CANCER VACCINES

6. PUBLIC HPV CANCER VACCINATION PROGRAM

7. GLOBAL CANCER VACCINES MARKET DYNAMICS

7.1 Favorable Market Parameters
  7.1.1 Pottential Demand for Cancer Vaccines
  7.1.2 Public Cancer Vaccination Program
  7.1.3 Advancements in Development Technology
  7.1.4 Personalized Cancer Vaccines
  7.1.5 Myriad of Demographs for Cancer Vaccine Development
7.2 Commercialization Challenges

8. GLOBAL CANCER VACCINE MARKET FUTURE OUTLOOK

9. BLADDER CANCER VACCINE CLINICAL PIPELINE INSIGHT BY COMPANY & PHASE

9.1 Phase-II

10. BLOOD CANCER VACCINE CLINICAL PIPELINE INSIGHT BY COMPANY & PHASE

10.1 Research till Preregistration

11. BRAIN CANCER VACCINE CLINICAL PIPELINE INSIGHT BY COMPANY & PHASE

11.1 Preclinical Till Phase-III

12. BREAST CANCER VACCINE CLINICAL PIPELINE INSIGHT BY COMPANY & PHASE

12.1 Preclinical till Phase-III

13. CANCER VACCINE CLINICAL PIPELINE INSIGHT BY COMPANY & PHASE

13.1 Research till Phase-II

14. CERVICAL CANCER VACCINE CLINICAL PIPELINE INSIGHT BY COMPANY & PHASE

14.1 Phase-II

15. COLORECTAL CANCER VACCINE CLINICAL PIPELINE INSIGHT BY COMPANY & PHASE

15.1 Preclinical till Preregistration

16. HEAD AND NECK CANCER VACCINE CLINICAL PIPELINE INSIGHT BY COMPANY & PHASE

16.1 Preclinical till Phase-I/II

17. LIVER CANCER VACCINE CLINICAL PIPELINE INSIGHT BY COMPANY & PHASE

17.1 Phase-I till Phase-II

18. LUNG CANCER VACCINE CLINICAL PIPELINE INSIGHT BY COMPANY & PHASE

18.1 Preclinical till Phase-III

19. OESOPHAGEAL CANCER VACCINE CLINICAL PIPELINE INSIGHT BY COMPANY & PHASE

19.1 Phase-III

20. OVARIAN CANCER VACCINE CLINICAL PIPELINE INSIGHT BY COMPANY & PHASE

20.1 Preclinical till Phase-III

21. PANCREATIC CANCER VACCINE CLINICAL PIPELINE INSIGHT BY COMPANY & PHASE

21.1 Reseach till Phase-III

22. PROSTATE CANCER VACCINE CLINICAL PIPELINE INSIGHT BY COMPANY & PHASE

22.1 Preclinical till Phase-III

23. RENAL CANCER VACCINE CLINICAL PIPELINE INSIGHT BY COMPANY & PHASE

23.1 Phase-I till Phase-III

24. SARCOMA VACCINE CLINICAL PIPELINE INSIGHT BY COMPANY & PHASE

24.1 Phase-II

25. SKIN CANCER VACCINE CLINICAL PIPELINE INSIGHT BY COMPANY & PHASE

25.1 Preclinical till Phase-III

26. SOLID TUMOURS VACCINE CLINICAL PIPELINE INSIGHT BY COMPANY & PHASE

26.1 Preclinical till Phase-II

27. MULTIPLE CANCER VACCINE CLINICAL PIPELINE INSIGHT BY COMPANY & PHASE

27.1 Preclinical till Phase-III

28. MARKETED CANCER VACCINE CLINICAL INSIGHT BY COMPANY & INDICATION

28.1 Bladder Cancer
  28.1.1 BCG Bladder Cancer Vaccine (Immucyst® & TheraCys®)
  28.1.2 Bladder Cancer Vaccine (PACIS®)
  28.1.3 Bladder Cancer Vaccine - Organon Teknika
28.2 Cervical Cancer
  28.2.1 Human Papillomavirus Vaccine Recombinant Bivalent (Cervarix®)
28.3 Lung Cancer
  28.3.1 BV NSCLC
  28.3.2 Cadi 05 (Immuvac® & Mycidac-C™)
  28.3.3 Racotumomab (Vaxira®)
28.4 Pancreatic Cancer
  28.4.1 Tertomotide (LucaVax)
28.5 Prostate Cancer
  28.5.1 Sipuleucel-T (Provenge®)
28.6 Renal Cancer
  28.6.1 Renal Cancer Vaccine (Reniale®)
  28.6.2 Vitespen (Oncophage®)
28.7 Skin Cancer
  28.7.1 Melanoma Vaccine (MVax®)
  28.7.2 Melanoma Vaccine (Melacine®)
28.8 Multiple Cancer
  28.8.1 Human Papillomavirus Vaccine 9-Valent (V503) (GARDASIL®9)
  28.8.2 Human Papillomavirus Vaccine Quadrivalent (Gardasil® & Silgard®)

29. DISCONTINUED & SUSPENDED CANCER VACCINE DRUG CLINICAL PIPELINE INSIGHT

29.1 No Development Reported
29.2 Discontinued
29.3 Suspended

30. FDA REGULATORY FRAMEWORK FOR CANCER VACCINES DEVELOPMENT & MARKETING

30.1 Considerations for both Early and Late Phase Clinical Trials
  30.1.1 Patient Population
  30.1.2 Monitoring the Immune Response
  30.1.3 Biomarkers as Evidence Of Efficacy
  30.1.4 Adjuvants Used To Stimulate Immune Response
  30.1.5 Multi-Antigen Vaccines
  30.1.6 Disease Progression/Recurrence Immediately Or Shortly After The Initial Administration Of Cancer Vaccines
  30.1.7 Concomitant and Subsequent Therapies
30.2 Considerations for Early Phase Clinical Trials
  30.2.1 Starting Dose and Dosing Schedule
  30.2.2 Booster and Maintenance Therapy
  30.2.3 Dose Escalation
  30.2.4 Single-Arm versus Randomized Phase 2 Trials In Early Development
30.3 Considerations for Late Phase Clinical Trials
  30.3.1 Safety Profile from Early Phase Clinical Trials
  30.3.2 Endpoints
  30.3.3 Statistical Issues
  30.3.4 Control Issues
  30.3.5 Delayed Vaccine Effect
  30.3.6 Autologous Vaccine Trials
  30.3.7 Accelerated Approval Regulations

31. COMPETITIVE LANDSCAPE: BUSINESS OVERVIEW & PRODUCT PIPELINE

31.1 Advaxis
31.2 AVAX Technologies
31.3 Celldex Therapeutics
31.4 Dendreon Corporation
31.5 Galena Biopharma
31.6 GlaxoSmithKline
31.7 ImmunoCellular Therapeutics
31.8 ImmunoGen
31.9 Inovio Pharmaceuticals
31.10 KAEL-GemVax
31.11 Liponova
31.12 MedImmune
31.13 Merck
31.14 NeoStem Oncology
31.15 NewLink Genetics
31.16 Northwest Biotherapeutics
31.17 Novartis
31.18 Peregrine Pharmaceuticals
31.19 Recombio
31.20 Roche
31.21 Sanofi
31.22 Seattle Genetics
31.23 Valeant Pharmaceuticals

List Of Figures

LIST OF FIGURES

Figure 1-1: Categorization & Function of Cancer Vaccines
Figure 2-1: Classification of Different Types of Cancer vaccines
Figure 4-1: Global Cancer Vaccines Market (US$ Billion), 2014-2020
Figure 4-2: Global Cancer Vaccines Market by Region (%), 2014 & 2020
Figure 4-3: Examples of Commercially Available Cancer Vaccines
Figure 4-4: Cancer Vaccine Drug Pipeline by Phase (%), 2015
Figure 4-5: Cancer Vaccine Drug Pipeline by Phase (Number), 2015
Figure 4-6: Bladder Cancer Vaccine Drug Pipeline by Phase (%), 2015
Figure 4-7: Bladder Cancer Vaccine Drug Pipeline by Phase (Number), 2015
Figure 4-8: Blood Cancer Vaccine Drug Pipeline by Phase (%), 2015
Figure 4-9: Blood Cancer Vaccine Drug Pipeline by Phase (Number), 2015
Figure 4-10: Brain Cancer Vaccine Drug Pipeline by Phase (%), 2015
Figure 4-11: Brain Cancer Vaccine Drug Pipeline by Phase (Number), 2015
Figure 4-12: Breast Cancer Vaccine Drug Pipeline by Phase (%), 2015
Figure 4-13: Breast Cancer Vaccine Drug Pipeline by Phase (Number), 2015
Figure 4-14: Cancer Vaccine Drug Pipeline by Phase (%), 2015
Figure 4-15: Cancer Vaccine Drug Pipeline by Phase (Number), 2015
Figure 4-16: Cervical Cancer Vaccine Drug Pipeline by Phase (%), 2015
Figure 4-17: Cervical Cancer Vaccine Drug Pipeline by Phase (Number), 2015
Figure 4-18: Colorecta Cancer Vaccine Drug Pipeline by Phase (%), 2015
Figure 4-19: Colorecta Cancer Vaccine Drug Pipeline by Phase (Number), 2015
Figure 4-20: Head & Neck Cancer Vaccine Drug Pipeline by Phase (%), 2015
Figure 4-21: Head & Neck Cancer Vaccine Drug Pipeline by Phase (Number), 2015
Figure 4-22: Liver Cancer Vaccine Drug Pipeline by Phase (%), 2015
Figure 4-23: Liver Cancer Vaccine Drug Pipeline by Phase (Number), 2015
Figure 4-24: Lung Cancer Vaccine Drug Pipeline by Phase (%), 2015
Figure 4-25: Lung Cancer Vaccine Drug Pipeline by Phase (%), 2015
Figure 4-26: Ovarian Cancer Vaccine Drug Pipeline by Phase (%), 2015
Figure 4-27: Ovarian Cancer Vaccine Drug Pipeline by Phase (%), 2015
Figure 4-28: Pancreatic Cancer Vaccine Drug Pipeline by Phase (%), 2015
Figure 4-29: Pancreatic Cancer Vaccine Drug Pipeline by Phase (Number), 2015
Figure 4-30: Prostate Cancer Vaccine Drug Pipeline by Phase (%), 2015
Figure 4-31: Prostate Cancer Vaccine Drug Pipeline by Phase (Number), 2015
Figure 4-32: Renal Cancer Vaccine Drug Pipeline by Phase (%), 2015
Figure 4-33: Renal Cancer Vaccine Drug Pipeline by Phase (Number), 2015
Figure 4-34: Skin Cancer Vaccine Drug Pipeline by Phase (%), 2015
Figure 4-35: Skin Cancer Vaccine Drug Pipeline by Phase (%), 2015
Figure 4-36: Solid Tumour Vaccine Drug Pipeline by Phase (%), 2015
Figure 4-37: Solid Tumour Vaccine Drug Pipeline by Phase (Number), 2015
Figure 4-38: Multiple Cancer Vaccine Drug Pipeline by Phase (%), 2015
Figure 4-39: Multiple Cancer Vaccine Drug Pipeline by Phase (Number), 2015
Figure 4-40: No Development Reported Cancer Vaccine Drug Pipeline by Phase (%), 2015
Figure 4-41: No Development Reported Cancer Vaccine Drug Pipeline by Phase (Number), 2015
Figure 4-42: Discontinued Cancer Vaccine Drug Pipeline by Phase (%), 2015
Figure 4-43: Discontinued Cancer Vaccine Drug Pipeline by Phase (Number), 2015
Figure 4-44: Suspended Cancer Vaccine Drug Pipeline by Phase (%), 2015
Figure 4-45: Suspended Cancer Vaccine Drug Pipeline by Phase (Number), 2015
Figure 5-1: Overview of Personalized Cancer Vaccines Development
Figure 5-2: Methodology for the Development of Personalized Cancer Vaccine
Figure 5-3: Schematic Representation of Development of Skin Implant for Cancer Vaccine
Figure 6-1: Prophylactic Cancer Vaccines Available for Different Serotypes of HPV
Figure 7-1: Factors Responsible for High Demand of Cancer Vaccines
Figure 31-1: Advaxis Clinical Pipeline
Figure 31-2: Celldex Therapeutics Clinical Pipeline
Figure 31-3: Galena Biopharma Clinical Pipeline
Figure 31-4: ImmunoCellular Therapeutics Clinical Pipeline
Figure 31-5: ImmunoGen Clinical Pipeline
Figure 31-6: Inovio Pharmaceuticals Clinical Pipeline
Figure 31-7: KAEL-Gemvax Clinical Pipeline
Figure 31-8: NewLink Genetics Corporation Clinical Pipeline
Figure 31-9: Northwest Biotherapeutics Clinical Pipeline
Figure 31-10: Peregrine Pharmaceuticals Clinical Pipeline
Figure 31-11: Seattle Genetics Clinical Pipeline

List Of Tables

LIST OF TABLES

Table 5-1: Different Types of Biomarkers For Personalized Cancer Vaccine Development

COMPANIES

Advaxis
AVAX Technologies
Celldex Therapeutics
Dendreon Corporation
Galena Biopharma
GlaxoSmithKline
ImmunoCellular Therapeutics
ImmunoGen
Inovio Pharmaceuticals
KAEL-GemVax
Liponova
MedImmune
Merck
NeoStem Oncology
NewLink Genetics
Northwest Biotherapeutics
Novartis
Peregrine Pharmaceuticals
Recombio
Roche
Sanofi
Seattle Genetics
Valeant Pharmaceuticals